Curi Wealth Management’s Humacyte HUMA Stock Holding History

Curi Wealth Management’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-35,440	Closed	-$101K	–	164
2023 Q2	$101K	Buy	+35,440	New	+$128K	0.01%	170

Other funds holding HUMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Curi Wealth Management's HUMA Position: Q3 2023 in Review

Curi Wealth Management sold out of Humacyte (HUMA) in Q3 2023, closing a stake of 35,440 shares — an estimated $101K sold.

Curi Wealth Management first reported a position in HUMA in Q2 2023 and held it in 1 quarter. The position peaked at $101K in Q2 2023. 83 funds tracked by Wall St. Rank hold HUMA as of Q3 2023.

Curi Wealth Management reported no remaining Humacyte position as of Q3 2023 after selling out during the quarter.
Curi Wealth Management sold 35,440 Humacyte shares in Q3 2023, an estimated $101K.
Curi Wealth Management first reported a position in Humacyte in Q2 2023 and held it in 1 quarter.
Curi Wealth Management's Humacyte position peaked at $101K in Q2 2023.
83 funds tracked by Wall St. Rank held Humacyte as of Q3 2023.

Based on Curi Wealth Management's 13F filing for Q3 2023, filed 6 Nov 2023.